- Integrated Analysis Reveals Critical Genomic Regions in Prostate Tumor Microenvironment Associated with Clinicopathologic Phenotypes
[作者：Ashida, S; Orloff, MS; Bebek, G; Zhang, L; Zheng, P; Peehl, DM; Eng, C,期刊：Clinical Cancer Research, 页码：1578-1587 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Recent studies suggest that tumor microenvironment (stroma) is important in carcinogenesis and progression. We sought to integrate global genomic structural and expressional alterations in prostate cancer epithe...
- Mechanisms of CHD5 Inactivation in Neuroblastomas
[作者：Koyama, H; Zhuang, TG; Light, JE; Kolla, V; Higashi, M; McGrady, PW; London, WB; Brodeur, GM,期刊：Clinical Cancer Research, 页码：1588-1597 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Neuroblastomas (NBs) have genomic, biological, and clinical heterogeneity. High-risk NBs are characterized by several genomic changes, including MYCN amplification and 1p36 deletion. We identified the chromatin-...
- Characterization of Gene Amplification-Driven SKP2 Overexpression in Myxofibrosarcoma: Potential Implications in Tumor Progression and Therapeutics
[作者：Li, CF; Wang, JM; Kang, HY; Huang, CK; Wang, JW; Fang, FM; Wang, YH; Wu, WR; Li, SH; Yu, SC; Lee, JC; Lan, J; Shiue, YL; Wu, LC; Huang, HY,期刊：Clinical Cancer Research, 页码：1598-1610 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Myxofibrosarcoma remains obscure in molecular determinants of clinical aggressiveness, for which we elucidated implications of SKP2 amplification. Experimental Design: Array comparative genomic hybridization was...
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
[作者：Green, MR; Rodig, S; Juszczynski, P; Ouyang, J; Sinha, P; O'Donnell, E; Neuberg, D; Shipp, MA,期刊：Clinical Cancer Research, 页码：1611-1618 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Programmed cell death ligand 1 (PD-L1) is a molecule expressed on antigen-presenting cells that engages the PD-1 receptor on T cells and inhibits T-cell receptor signaling. The PD-1 axis can be exploited by tumo...
- Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non-Small Cell Lung Cancers
[作者：Heller, G; Weinzierl, M; Noll, C; Babinsky, V; Ziegler, B; Altenberger, C; Minichsdorfer, C; Lang, G; Dome, B; End-Pfutzenreuter, A; Arns, BM; Grin, Y; Klepetko, W; Zielinski, CC; Zochbauer-Muller, S,期刊：Clinical Cancer Research, 页码：1619-1629 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: The major aim of this study was to investigate the role of DNA methylation (referred to as methylation) on miRNA silencing in non-small cell lung cancers (NSCLC). Experimental Design: We conducted microarray exp...
- Interleukin-27 Inhibits the Growth of Pediatric Acute Myeloid Leukemia in NOD/SCID/Il2rg (-/-) Mice
[作者：Zorzoli, A; Di Carlo, E; Cocco, C; Ognio, E; Ribatti, D; Ferretti, E; Dufour, C; Locatelli, F; Montagna, D; Airoldi, I,期刊：Clinical Cancer Research, 页码：1630-1640 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Acute myeloid leukemia (AML) accounts for more than half of fatal cases in all pediatric leukemia patients; this observation highlights the need of more effective therapies. Thus, we investigated whether interle...
- Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis
[作者：Takahashi, O; Komaki, R; Smith, PD; Jurgensmeier, JM; Ryan, A; Bekele, BN; Wistuba, II; Jacoby, JJ; Korshunova, MV; Biernacka, A; Erez, B; Hosho, K; Herbst, RS; O'Reilly, MS,期刊：Clinical Cancer Research, 页码：1641-1654 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Ras/Raf/mitogen-activated protein-extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling is critical for tumor cell proliferation and survival. Selumetinib is a potent, selective, and orally avai...
- Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
[作者：Wang, W; Li, Q; Takeuchi, S; Yamada, T; Koizumi, H; Nakamura, T; Matsumoto, K; Mukaida, N; Nishioka, Y; Sone, S; Nakagawa, T; Uenaka, T; Yano, S,期刊：Clinical Cancer Research, 页码：1663-1671 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Hepatocyte growth factor (HGF) induces resistance to reversible and irreversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in EGFR mutant lung cancer cells by activating Met and the ...
- Local Delivery of Interleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
[作者：Chinnasamy, D; Yu, ZY; Kerkar, SP; Zhang, L; Morgan, RA; Restifo, NP; Rosenberg, SA,期刊：Clinical Cancer Research, 页码：1672-1683 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: We investigated the feasibility of delivering the proinflammatory cytokine interleukin (IL)-12 into tumor using T cells genetically engineered to express a chimeric antigen receptor (CAR) against the VEGF recept...
- The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia
[作者：Wang, JL; Foehrenbacher, A; Su, JC; Patel, R; Hay, MP; Hicks, KO; Wilson, WR,期刊：Clinical Cancer Research, 页码：1684-1695 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Benzotriazine-N-oxide bioreductive prodrugs such as tirapazamine and its improved analogue CEN-209 (SN30000) have potential for exploiting hypoxia in tumors. Here, we test the hypothesis that the 2-nitroimidazol...
- Relationship between F-18-Fluorodeoxyglucose Accumulation and KRAS/BRAF Mutations in Colorectal Cancer
[作者：Kawada, K; Nakamoto, Y; Kawada, M; Hida, K; Matsumoto, T; Murakami, T; Hasegawa, S; Togashi, K; Sakai, Y,期刊：Clinical Cancer Research, 页码：1696-1703 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Positron emission tomography (PET) with F-18-fluorodeoxyglucose (FDG) has been widely used in the management of colorectal cancer (CRC). However, the relationship between FDG accumulation and KRAS/BRAF mutations...
- Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women
[作者：Servant, N; Bollet, MA; Halfwerk, H; Bleakley, K; Kreike, B; Jacob, L; Sie, D; Kerkhoven, RM; Hupe, P; Hadhri, R; Fourquet, A; Bartelink, H; Barillot, E; Sigal-Zafrani, B; van de Vijver, MJ,期刊：Clinical Cancer Research, 页码：1704-1715 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: A gene expression signature, predictive for local recurrence after breast-conserving treatment, has previously been identified from a series of 165 young patients with breast cancer. We evaluated this signature ...
- Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy
[作者：Perl, AE; Kasner, MT; Shank, D; Luger, SM; Carroll, M,期刊：Clinical Cancer Research, 页码：1716-1725 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Integration of signal transduction inhibitors into chemotherapy regimens generally has generally not led to anticipated increases in response and survival. However, it remains unclear whether this is because of ...
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
[作者：Kummar, S; Ji, JP; Morgan, R; Lenz, HJ; Puhalla, SL; Belani, CP; Gandara, DR; Allen, D; Kiesel, B; Beumer, JH; Newman, EM; Rubinstein, L; Chen, A; Zhang, YP; Wang, LH; Kinders, RJ; Parchment, RE; Tomaszewski, JE; Doroshow, JH,期刊：Clinical Cancer Research, 页码：1726-1734 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Oral administration of the alkylating agent cyclophosphamide at low doses, metronomic dosing, is well tolerated, with efficacy in multiple tumor types. PARP inhibition potentiates effects of cyclophosphamide in ...
- A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck
[作者：Gilbert, J; Rudek, MA; Higgins, MJ; Zhao, M; Bienvenu, S; Tsottles, N; Wahl, R; Forastiere, A; Gillison, M,期刊：Clinical Cancer Research, 页码：1735-1742 , 文章类型： Article，,卷期：2012年18-6]
- Purpose: Erlotinib, an orally active selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, has synergistic activity with radiation and with cisplatin. The EGFR is overexpressed in the majori...
|